ISCO welcomes Dr. Frank Cloutier to its research team.  Dr. Cloutier just completed his post-graduate
work with Dr. Hans Keirstead at UCI.  He will continue to work at the UCI laboratory to transfer stem cell culture technology to the Oceanside, CA laboratory in anticipation of collaborative work with
Dr. Keirstead and the Reeve Irvine Research Center at UCI.  Dr. Cloutier is part of the Lifeline team
working on the clinical use of stem cells for treatment of retinal disease.

Welcome to Dr. Bernard M. Wagner, MD,
the latest member of Lifeline’s Scientific Advisory Board

Dr. Wagner will be a valuable addition to Lifeline’s SAB, especially in Lifeline’s interactions with the FDA
for the manufacture and testing of cells for future therapeutic use.  Bernard M. Wagner, MD is an
Emeritus Research Professor of Pathology, New York University Medical Center and Emeritus Clinical
Professor of Pathology, College of Physicians & Surgeons, Columbia University, New York. He is a
Diplomat, of the American Board of Pathology and Diplomat (Hon.), of the American College of Veterinary Pathologists. Dr. Wagner is also a Fellow of the Royal College of Pathologists (London);
Fellow, Academy of Toxicologic Sciences; Fellow, New York Academy of Medicine; Member, Committee
on Toxicology, National Academy of Sciences; Qualified Expert, European Council, Safety Assessment;
Member Executive Committee, Board of Directors, American Registry of Pathology, Armed Forces
Institute of Pathology; Member, GRAS Expert Panel (FDA); and Fellow of American Academy of Arts and Sciences. Currently, he is a Senior Consultant for Roche and Consultant for ICOS Corp.

Manufacturing

Our manufacturing capacities are improving and expanding.  Last week we produced our 59^th consecutive “lot” of product.  The latest lot consisted of 800 units and utilized a new “bag process” that minimized exposure of product to the outside environment.  All lots manufactured in our new clean room have been sterile to date.  This accomplishment is a necessary step towards establishing technologies at Lifeline for the eventual cGMP production clinical products.

Progress to Date

Although a young company, ISCO has  built a portfolio of success.

• Secured exclusive worldwide therapeutic rights to use leading technologies to create embryonic stem cells and to derive cells suitable for the treatment of diabetes, liver and retinal disease.
• Employs a team of world-recognized scientific staff in human cell culture. ISCO's scientific team has training and experience in the unique protocols and techniques needed to:
  • Employ techniques to create stem cells that have the potential to avoid immune rejection using parthenogenesis and somatic cell nuclear transfer (SCNT),
  • Create animal-free cell culture media for the culture of cells without contamination.
  • Create human retinal cells from stem cells for use in early stage clinical trials
  • Manufacture cells and culture medium under cGMP conditions suitable for FDA approval.
• Assembled a management team with proven track records in developing, manufacturing, marketing and selling human cells for research and therapeutic use.
• Set up a Scientific Advisory Board staffed with experts with broad knowledge in the fields necessary to create and test cells for therapeutic use, including the fields of human embryonic stem cell culture, molecular biology and regulatory compliance.
• Developed and launched the Lifeline brand of research products for the culture of human cells – including FibroLife™ products for the culture of human stem cells.
• Built-out and equipped a manufacturing and development laboratory in Maryland staffed to develop research products focused on human cell culture.
• Opened a facility in Oceanside California to consolidate R&D and build out a prototype facility for the production of therapeutic cells derived from stem cells for early-stage clinical trials.

Research Donation Opportunities

•   ISCO has made arrangements that will permit tax deductible donations to be made to accelerate its therapeutic research into stem-cell-based retinal degenerative disease research. 

•   All funds are managed by the Reeve-Irvine Research Center Keirstead Lab Retinal Project, through the not-for-profit “University of California at Irvine Foundation (UCI Foundation).

Interested donors should contact:

 Mr. William B. Adams, CPA, Managing Member and CFO,
(310) 472-3017, billa@lifelinecelltech.com.